Company / R&D Expense
NEUROONE MEDICAL TECHNOLOGIES Corp R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$5.1M
FY2025
5-year range
$2.1M / $6.9M
FY2021-FY2025
Trend
-27.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2025 with a 3-year CAGR of +8.9%.
Improved from $5M to $5M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +8.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 27.0% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.1M | -27.0% |
| FY2024 | $6.9M | +40.8% |
| FY2023 | $4.9M | +25.6% |
| FY2022 | $3.9M | +89.1% |
| FY2021 | $2.1M | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026